摘要
目的探讨氨磺必利与利培酮治疗首发精神分裂症的临床疗效和安全性。方法将62例精神分裂症患者按照随机数字表法分为两组，每组31例，分别口服氨磺必利、利培酮治疗，观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗第8周末，氨磺必利组阳性与阴性症状量表阳性症状分减分值显著高于利培酮组（P〈0．05），阴性症状分减分值显著低于利培酮组（P〈O．05）；氨磺必利组显效率为74．2％、有效率为96．8％，利培酮组分别为77．4％、93．5％，两组比较差异无显著性（X2=0．09、0．35，P〉0．05）。氨磺必利组体质量增加、锥体外系反应和血糖升高发生率显著低于利培酮组（P〈0．05），其他不良反应发生率两组比较差异无显著性（P〉0．05）。结论氨磺必利治疗精神分裂症的疗效与利培酮相当，但安全性更高，依从性更好。
Objective To explore the efficacy and safety of amisulpride and risperidone in the treatment of first-episode schizophrenia. Methods Sixty-two first-episode schizophrenics were assigned to two groups of 31 ones each according to random number table, took orally amisulpride or risperidone for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS）and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results At the end of the 8th week decreased score of positive symptoms of the PANSS was significantly higher （P〈0.05） and negative lower （P〈0.05） in amisulpride than in risperidone group; obvious effective and effective rate were respectively 74.2% and 96.8% in amisulpride and 77.4% and 93.5% risperidone group, which showed no significant group differences （X2=0. 09,0.35; P〉0.05）. The incidences of weight gain, extrapyramidal side effects and blood glucose elevation were significantly lower in amisulpride than in risperidone group （P〈0.05）, there were no significant group differences in those of other adverse reactions （P〉0.05）. Conclusion Amisulpride has an equivalent efficacy to risperidone in schizophrenia, but its safety is higher and compliance better.
出处
《临床心身疾病杂志》
CAS
2016年第2期56-58,共3页
Journal of Clinical Psychosomatic Diseases
